GBT · Global Blood Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $1.41M | $1.05M | - | $830.0K | $748.0K | $584.0K | - | $513.0K | $377.0K | $135.0K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $64.78M | $52.83M | - | $50.53M | $51.78M | $50.86M | - | $40.20M | $34.09M | $39.77M |
| SG&A | $81.09M | $74.53M | - | $67.99M | $61.09M | $58.97M | - | $54.49M | $49.08M | $47.66M |
| Total Operating Expenses | $147.28M | $128.42M | - | $119.35M | $113.63M | $110.41M | - | $95.20M | $60.80M | $87.57M |
| D&A | - | $1.52M | - | - | - | $1.40M | - | - | - | $2.24M |
| Operating Income | ($75.73M) | ($73.26M) | - | ($67.29M) | ($66.07M) | ($71.36M) | - | ($58.31M) | ($52.04M) | ($73.45M) |
| Interest Expense | - | $98.44M | - | - | - | $45.56M | - | - | - | $29.53M |
| Income Tax | $192.0K | $123.0K | - | - | - | - | - | - | - | - |
| Net Income | ($82.47M) | ($81.42M) | - | ($70.99M) | ($69.59M) | ($74.93M) | - | ($59.88M) | ($52.84M) | ($73.03M) |
| EPS - Basic | ($1.12) | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | ($1.12) | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $261.15M | $391.80M | $684.72M | $382.87M | $419.31M | $445.31M | $494.77M | $418.40M | $384.72M | $315.52M |
| Accounts Receivable | $29.77M | $27.73M | $28.80M | $23.89M | $19.54M | $18.27M | $17.50M | $14.13M | $12.47M | $4.58M |
| Inventory | $65.82M | $61.96M | $58.20M | $51.51M | $47.99M | $42.27M | $40.22M | $33.81M | $27.33M | $14.93M |
| Accounts Payable | $8.26M | $5.42M | $15.10M | $8.64M | $9.20M | $10.38M | $19.08M | $7.88M | $5.69M | $13.70M |
| Current Assets | $640.01M | $675.65M | $801.97M | $488.86M | $524.86M | $558.13M | $632.16M | $594.66M | $594.03M | $564.47M |
| Total Assets | $870.44M | $869.54M | $939.21M | $607.68M | $614.97M | $649.90M | $724.00M | $691.26M | $721.67M | $741.15M |
| Current Liabilities | $93.09M | $79.31M | $88.00M | $74.06M | $72.67M | $58.97M | $79.03M | $77.95M | $69.40M | $62.25M |
| Long-term Debt | $247.13M | $246.74M | $246.35M | $149.51M | $149.27M | $149.05M | $148.81M | $73.88M | $73.78M | $73.69M |
| Total Liabilities | $752.08M | $735.54M | $742.80M | $299.38M | $299.21M | $286.70M | $307.85M | $233.61M | $225.85M | $217.57M |
| Stockholders' Equity | $118.36M | $134.00M | $196.41M | $308.30M | $315.77M | $363.19M | $416.16M | $457.65M | $495.82M | $523.57M |
| Retained Earnings | ($1.45B) | ($1.37B) | ($1.29B) | ($1.20B) | ($1.13B) | ($1.06B) | ($986.47M) | ($924.66M) | ($864.78M) | ($811.94M) |
Cash Flow
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($71.85M) | - | - | - | ($79.26M) | - | - | - | ($78.62M) |
| Investing Cash Flow | - | ($222.50M) | - | - | - | $28.00M | - | - | - | $91.13M |
| Financing Cash Flow | - | $1.60M | - | - | - | $1.78M | - | - | - | $784.0K |
| CapEx | - | $252.0K | - | - | - | $1.13M | - | - | - | $2.52M |
| Free Cash Flow | - | ($72.11M) | - | - | - | ($80.39M) | - | - | - | ($81.15M) |
Ratios
| Metric | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | 0.89 | - | - | - | 1.07 | - | - | - | 1.11 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.5% | -9.4% | - | -11.7% | -11.3% | -11.5% | - | -8.7% | -7.3% | -9.9% |
| Return on equity | -69.7% | -60.8% | - | -23.0% | -22.0% | -20.6% | - | -13.1% | -10.7% | -13.9% |
| Return on invested capital | -16.4% | -15.2% | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.88 | 8.52 | 9.11 | 6.60 | 7.22 | 9.47 | 8.00 | 7.63 | 8.56 | 9.07 |
| Quick ratio | 6.17 | 7.74 | 8.45 | 5.91 | 6.56 | 8.75 | 7.49 | 7.20 | 8.17 | 8.83 |
| Cash ratio | 2.81 | 4.94 | 7.78 | 5.17 | 5.77 | 7.55 | 6.26 | 5.37 | 5.54 | 5.07 |
| Leverage | ||||||||||
| Debt / Equity | 2.09 | 1.84 | 1.25 | 0.48 | 0.47 | 0.41 | 0.36 | 0.16 | 0.15 | 0.14 |
| Debt / Assets | 0.28 | 0.28 | 0.26 | 0.25 | 0.24 | 0.23 | 0.21 | 0.11 | 0.10 | 0.10 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | -0.7x | - | - | - | -1.6x | - | - | - | -2.5x |
| Equity multiplier | 7.35 | 6.49 | 4.78 | 1.97 | 1.95 | 1.79 | 1.74 | 1.51 | 1.46 | 1.42 |
| Liabilities / Assets | 0.86 | 0.85 | 0.79 | 0.49 | 0.49 | 0.44 | 0.43 | 0.34 | 0.31 | 0.29 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 0.02 | 0.02 | - | 0.02 | 0.02 | 0.01 | - | 0.02 | 0.01 | 0.01 |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 17001d | 21438d | - | 22653d | 23418d | 26417d | - | 24054d | 26464d | 40358d |
| Days payable outstanding | 2134d | 1876d | - | 3800d | 4488d | 6485d | - | 5608d | 5509d | 37030d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -14.6% | -2.7% | - | -15.4% | -27.0% | 2.8% | - | 15.2% | 14.4% | -39.8% |
| Net income growth (YoY) | -18.5% | -8.7% | - | -18.5% | -31.7% | -2.6% | - | 7.2% | 7.8% | -49.3% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 10.3% | - | - | - | 0.9% | - | - | - | -120.4% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -62.5% | -63.1% | -52.8% | -32.6% | -36.3% | -30.6% | -28.1% | -30.5% | -29.6% | -5.9% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Global Blood Therapeutics against the 5 most active filers in the same SIC group.